Our focus is on diseases which are modulated by the host immune response. We use a virtual biotech model to identify clinical-stage assets for high-value development which is designed to unlock major benefits for both patients and shareholders. Where possible, we leverage our investor capital with non-dilutive funding by directing our effort at disease targets with high national strategic value.

Please click here to listen to a Shareholders briefing 15 October 2008.

(Note this file is password protected. Please email your name, phone number and company name to info@implicitbioscience.com for access details)